March 14, 2024Open Access

Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

This pooled analysis of patient-level data from trials evaluated the clinical outcomes of patients with metastatic renal cell carcinoma with or without cytoreductive nephrectomy before a combination of immune checkpoint inhibitor and antiangiogenic therapy.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Fallah et al. (Thu,) studied this question.

synapsesocial.com/papers/68e73fecb6db6435876b99cd https://doi.org/https://doi.org/10.1093/jnci/djae066

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium2022 · 106 citations
2New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)2008 · 29,472 citations
3Primary 4T1 tumor resection provides critical “window of opportunity” for immunotherapy2013 · 31 citations
4The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells2012 · 812 citations
5Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden2013 · 125 citations

Me gusta

Guardar

Ver artículo completo